Opioid analgesic with dual mechanism
ATC code: N02AX06 (Tapentadol)
Brand names
Palexia, Nucynta, Yantil, Palexia Retard
Dual mechanism: μ-opioid agonist and noradrenaline reuptake inhibitor. The combination yields analgesia comparable to oxycodone with 30–50% lower typical opioid side effects (nausea, vomiting, constipation) per the Riemsma 2011 meta-analysis. No active metabolites, so less affected by CYP polymorphism than tramadol. Half-life 4 hours for immediate-release, 5–6 hours for extended-release.
Second line
In acute moderate-to-severe pain (postoperative, musculoskeletal), the immediate-release form is used at 50–100 mg every 4–6 hours. Course is limited to a few days to prevent dependence. Not first-line – and adequate NSAID dosing come first.
Second line
Used in moderate-to-severe chronic pain, particularly with mixed nociceptive-neuropathic components. NG193 (2021) does not place opioids as first-line in chronic non-cancer pain; they are considered when alternatives fail. Extended-release starting dose 50 mg twice daily, titrated to 250 mg twice daily. Compared with oxycodone, less constipation and nausea.
The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.
Not recommended
Tapentadol is an opioid analgesic with additional norepinephrine reuptake inhibitor activity. It is prescribed for moderate-to-severe chronic pain when other drugs are ineffective (AEMPS Ficha Técnica). For chronic fatigue without a confirmed pain syndrome, tapentadol is strictly not indicated. The drug has serious risks: opioid dependence formation ( boxed warning), respiratory depression (life-threatening, especially combined with other CNS depressants), serotonin syndrome with other serotonergic drugs, sedation, constipation, and nausea. If tapentadol was prescribed for fatigue, seek a second opinion immediately.
Opens the checker prefilled with this drug. Pick the second one from your regimen.
Direct links to regulator labels. Open in a new tab.
Boxed warning
FDA boxed warning: risk of addiction, abuse, severe respiratory depression, and death. Combination with benzodiazepines, alcohol, gabapentin, or pregabalin is hazardous. Prescribe only for clear indications, at minimum effective dose, with scheduled review.
Long-term use in T3 carries neonatal abstinence syndrome risk. For chronic pain in pregnancy, non-opioid measures are first-line; when an opioid is needed, short-term lowest-effective dose is preferred.
Limited data. Use cautiously in lactation with monitoring of infant sedation and activity.
Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.
Tapentadol is evaluated for the following indications with varying evidence strength: Acute mild-to-moderate pain (evidence tier B), Moderate-to-severe chronic pain (evidence tier B), Chronic fatigue (evidence tier F). See the full indication matrix with dosing and citations above on this page.
Common side effects of Tapentadol (≥ 1 in 100): Nausea, Constipation, Drowsiness, Dizziness, Dry mouth, Pruritus. See the Safety section for uncommon and serious reactions.
FDA category C. Long-term use in T3 carries neonatal abstinence syndrome risk. For chronic pain in pregnancy, non-opioid measures are first-line; when an opioid is needed, short-term lowest-effective dose is preferred.
Limited data. Use cautiously in lactation with monitoring of infant sedation and activity.
Tapentadol is contraindicated in: Tapentadol hypersensitivity; Severe respiratory failure, acute bronchospasm; Severe hepatic impairment; Acute alcohol or opioid intoxication; Concurrent MAO inhibitors or within 14 days of stopping. Full list in the Safety section.
FDA boxed warning: risk of addiction, abuse, severe respiratory depression, and death. Combination with benzodiazepines, alcohol, gabapentin, or pregabalin is hazardous. Prescribe only for clear indications, at minimum effective dose, with scheduled review.